Literature DB >> 23918948

The time is ripe for a randomized trial of metformin in clinically localized prostate cancer.

Kathryn L Penney, Meir J Stampfer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23918948     DOI： 10.1200/JCO.2013.50.7715

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.

Authors:  M R Danzig; S Kotamarti; R A Ghandour; M B Rothberg; B P Dubow; M C Benson; K K Badani; J M McKiernan
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-18       Impact factor: 5.554

2.  Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.

Authors:  Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.554

3.  Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.

Authors:  Hongliang Yu; Li Yin; Xuesong Jiang; Xiujin Sun; Jing Wu; Hao Tian; Xianshu Gao; Xia He
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

4.  Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.

Authors:  Al V Taira; Gregory S Merrick; Robert W Galbreath; Mallory Morris; Wayne M Butler; Edward Adamovich
Journal:  J Contemp Brachytherapy       Date:  2014-10-06

5.  Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.

Authors:  Rongbin Ge; Zongwei Wang; Shulin Wu; Yangjia Zhuo; Aleksandar G Otsetov; Chao Cai; Weide Zhong; Chin-Lee Wu; Aria F Olumi
Journal:  Oncotarget       Date:  2015-10-06

6.  Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Authors:  Danielle Crawley; Ashish Chandra; Massimo Loda; Cheryl Gillett; Paul Cathcart; Ben Challacombe; Gary Cook; Declan Cahill; Aida Santa Olalla; Fidelma Cahill; Gincy George; Sarah Rudman; Mieke Van Hemelrijck
Journal:  BMC Cancer       Date:  2017-07-21       Impact factor: 4.430

7.  Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.

Authors:  Julian O Kim; Megan O McDonald; Aldrich Ong; Rashmi Koul; Arbind Dubey; William Hunter; Shahida Ahmed; Harvey Quon; Don Yee; Matthew Parliament; Gokulan Sivananthan; Brita Danielson; Lindsay Rowe; Sunita Ghosh; Nawaid Usmani
Journal:  Radiat Oncol       Date:  2021-11-04       Impact factor: 3.481

Review 8.  A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Authors:  Danielle Crawley; Florence Chamberlain; Hans Garmo; Sarah Rudman; Björn Zethelius; Lars Holmberg; Jan Adolfsson; Par Stattin; Paul Carroll; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2018-01-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.